Recognition highlights Takeda’s continued efforts in reducing greenhouse gas emissions and leading the state to a clean energy future.
CAMBRIDGE, Massachusetts, October 4, 2023 — Takeda (TSE:4502/NYSE:TAK) is pleased to announce its Lexington site has been selected as a 2023 Mass Save® Climate Leader. Takeda is one of fourteen commercial and industrial organizations across the Commonwealth to receive this distinguished recognition.
“On behalf of Takeda, I am deeply honored to receive the 2023 Mass Save Climate Leader Award,” said James Hayes, head of environmental health and safety of Takeda. “This award serves as a testament to the collective commitment and dedication of our team and partners who have worked tirelessly towards the goal of mitigating climate change and promoting energy efficiency. It reinforces our belief that every small step taken toward environmental responsibility has a significant impact on our planet.”
Takeda has made significant investments in energy efficiency and sustainability across our Massachusetts buildings. Through leveraging financial and technical support provided by the Sponsors of Mass Save, we have been able to drastically reduce energy consumption and curb greenhouse gas emissions by over 8,000 tons CO2e annually. Specific projects include energy recovery, HVAC system controls and EMS, lighting and equipment upgrades, and electrification. Takeda’s recent virtual power purchasing agreement for 100% renewable energy avoids an additional 20,000 tons CO2e from these sites.
This award recognizes the efforts Takeda is taking to reach its ambitious environmental goals, including achieving net-zero greenhouse gas emissions for scopes 1 and 2 before 2035, and for its entire value chain, including currently estimated1scope 3 GHG emissions, before 20402.
“The 2023 Climate Leaders recognize the importance of battling the climate crisis, having each taken crucial steps towards creating a sustainable future through increased energy efficiency,” said Christopher Porter, Director of Customer Energy Management at National Grid. “This year’s Climate Leaders exemplify the commitments necessary to achieve, and serve as a role model for, the Commonwealth’s clean energy economy and climate objectives. We appreciate the recipients’ efforts and look forward to continued collaboration with all our partners to achieve Massachusetts’ net-zero goals.”
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.